NIH Begins Clinical Trial of Hydroxychloroquine, a Potential Therapy for COVID-19

From TechStartups.com
After many controversies surrounding the anti-malaria hydroxychloroquine, the National Institutes of Health announced on Thursday it has begun the clinical trial of Hydroxychloroquine. In a press release, the agency said the clinical trial will evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with coronavirus disease 2019 (COVID-19) has begun, with the first participants now enrolled in Tennessee.
The Outcomes Related to COVID-19 treated with hydroxychloroquine among In-patients with symptomatic Disease study, or ORCHID Study, is being conducted by the Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network of the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.